Success Metrics

Active Trials
5(100%)

Phase Distribution

Ph phase_2
4
80%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

recruiting5100%

Recent Activity

5 active trials
Showing 5 of 5
recruitingphase_2

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

NCT07572383
recruitingphase_2

Advanced Imaging for Pulmonary Fibrosis

NCT06532071
recruitingphase_2

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

NCT05417776
recruitingphase_2

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

NCT04485286
recruitingphase_1

Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients

NCT03535545

Clinical Trials (5)

Showing 5 of 5 trials
NCT07572383Phase 2

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

Recruiting
NCT06532071Phase 2

Advanced Imaging for Pulmonary Fibrosis

Recruiting
NCT05417776Phase 2

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Recruiting
NCT04485286Phase 2

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

Recruiting
NCT03535545Phase 1

Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5